Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
Autore:
Tsuchida, K; Makita, Z; Yamagishi, S; Atsumi, T; Miyoshi, H; Obara, S; Ishida, M; Ishikawa, S; Yasumura, K; Koike, T;
Indirizzi:
Hokkaidoanniv, Sch Med, Dept Med 2, Kita Ku, Sapporo, Hokkaido 0608683, Jap Hokkaido Univ Sapporo Hokkaido Japan 0608683 pporo, Hokkaido 0608683, Jap Kanazawa Univ, Sch Med, Dept Biochem, Kanazawa, Ishikawa 920, Japan Kanazawa Univ Kanazawa Ishikawa Japan 920 , Kanazawa, Ishikawa 920, Japan Otsuka Pharmaceut, Fujii Mem Res Inst, Ohtsu, Shiga, Japan Otsuka Pharmaceut Ohtsu Shiga Japan ii Mem Res Inst, Ohtsu, Shiga, Japan
Titolo Testata:
DIABETOLOGIA
fascicolo: 5, volume: 42, anno: 1999,
pagine: 579 - 588
SICI:
0012-186X(199905)42:5<579:SOTGFB>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUCOSE-MODIFIED PROTEINS; MATRIX GENE-EXPRESSION; ADVANCED GLYCOSYLATION; EXTRACELLULAR-MATRIX; PERMEABILITY FACTOR; KIDNEY-DISEASE; MESANGIAL EXPANSION; RECENT PROGRESS; TGF-BETA; CELLS;
Keywords:
type II diabetes mellitus; extracellular matrix; glomerulosclerosis; type IV collagen; Otsuka-Long-Evans-Tokushima-Fatty rat;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
59
Recensione:
Indirizzi per estratti:
Indirizzo: Makita, Z Hokkaido08683, Sch Med, Dept Med 2, Kita Ku, N-15,W-7, Sapporo, Hokkaido 06 Hokkaido Univ N-15,W-7 Sapporo Hokkaido Japan 0608683 okkaido 06
Citazione:
K. Tsuchida et al., "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195", DIABETOLOG, 42(5), 1999, pp. 579-588

Abstract

Aims/hypothesis. Advanced glycation end products (AGEs) participate in thepathogenesis of diabetic nephropathy. We reported earlier that OPB-9195, asynthetic thiazolidine derivative and novel inhibitor of advanced glycation, prevented progression of diabetic glomerulosclerosis by lowering serum concentrations of advanced glycation end products and reducing their deposition in the glomeruli. Here, we examined their contribution and that of growth factors, such as transforming growth factor-beta (TGF-beta) and vascularendothelial growth factor (VEGF), to the progression of diabetic nephropathy. We also investigated the expression of type IV collagen in the kidneys of Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats, a Type II (non-insulin-dependent) diabetes mellitus model, after treatment with OPB-9195. Methods. Using northern blots and immunohistochemical techniques, we determined the renal expression of TGF-beta and type IV collagen mRNAs and proteins in OLETF rats. We also examined OPB-9195's effects on renal expression of VEGF mRNA and protein. Results. Concomitant increases in TGF-beta and type IV collagen expressionwere observed at each point in time in OLETF rats not given OPB-9195. In contrast, OPB-9195 treatment greatly suppressed the renal expression of TGF-beta, VEGF and type IV collagen mRNAs and proteins to that seen in non-diabetic rats. Conclusion/interpretation. Since OPB-9195, an AGE-inhibitor, prevented theprogression of diabetic nephropathy by blocking type IV collagen production and suppressing overproduction of two growth factors, TGF-beta and VEGF, in diabetic rats, this compound warrants further investigation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 12:08:51